Kala Pharmaceuticals (KALA) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. SPY
7. MSFT
8. SKYD
9. LEVI
10. APLD

Go back to Kala Pharmaceuticals (KALA) Reports In-Line Q2 EPS

Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 6, 2020 7:00 AM EDT

-- EYSUVIS NDA Accepted by FDA; Assigned PDUFA Goal Date of October 30, 2020 --
-- 2Q 2020 INVELTYS® Revenue of $0.8 Million --
-- Conference Call and Webcast at 8:00 a.m. ET --

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2020.

We are very pleased with our progress in the second quarter, said Mark Iwicki,... More